Dr Keenan and colleagues at UCSF's Proctor Foundation have demonstrated (in the MORDOR I study) that twice-yearly azithromycin administration to children in various African countries reduced childhood mortality significantly. Recently they followed up with MORDOR II (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance). They examined whether, continued administration would induce antibiotic resistance and decrease efficacy, or whether community wide reduction of bacteria would increase efficacy. In tandem, they explored whether azithromycin, which has antimalarial activity, reduces the community burden of malaria. The trial evaluated childhood mortality in various Niger communities who had and had not received azithromycin the previous 2 years.
Jeremy Keenan, MD, MPH, is the Director of International Programs at the Proctor Foundation. He is part of the Proctor teams conducting randomized trials investigating trachoma elimination strategies (Ethiopia), the role of mass azithromycin distributions for reducing childhood mortality (Niger), and the effectiveness of village health workers for preventing corneal ulcers (Nepal). He is also involved in diagnostic studies investigating conventional and novel screening tools for glaucoma and diabetic retinopathy (India, Thailand), and conducts observational epidemiological studies on acanthamoeba keratitis (India, USA) and cytomegalovirus retinitis (Thailand).
Please join the Dept of Pediatrics and the Institute for Global Health Sciences in welcoming Dr Keenan, as part of the 5th Annual Global Child Health Lecture Series.
Wednesday, August 28 at 9:00am to 10:00am
Mission Hall, 1406
550 16th St, San Francisco, CA 94158